课题基金 / 基金详情

Task 18 (D24) Efficacy Testing of Therapeutics Against Inhalational Anthrax

Task 18 (D24) Efficacy Testing of Therapeutics Against Inhalational Anthrax
任务 18 (D24) 吸入性炭疽治疗药物的功效测试
批准号:
8672503
负责人:
金额:
$56.3万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-27 至 2014-02-28

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The In Vitro and Animal Models for Emerging Diseases and Biodefense contract provides the development and standardization of small animal and non-human primate models, and may include efficacy testing of vaccines and/or therapeutics, including GLP studies to support product licensure. Vaccines and therapeutics which are efficacious in small animals may be further tested in non-human primate models. This contract also provides testing of vaccines for safety and immunogenicity, to include humoral and cellular immunity, in small animals as well as non-human primates, under GLP where appropriate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金